Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.

doi:10.1186/s12916-017-0842-4

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.

BMC medicine - 24 Apr 2017

Dahourou Désiré Lucien, Amorissani-Folquet Madeleine, Malateste Karen, Amani-Bosse Clarisse, Coulibaly Malik, Seguin-Devaux Carole, Toni Thomas, Ouédraogo Rasmata, Blanche Stéphane, Yonaba Caroline, Eboua François, Lepage Philippe, Avit Divine, Ouédraogo Sylvie, Van de Perre Philippe, N'Gbeche Sylvie, Kalmogho Angèle, Salamon Roger, Meda Nicolas, Timité-Konan Marguerite, Leroy Valériane

Abstract excerpt

BACKGROUND: The 2016 World Health Organization guidelines recommend all children <3 years start antiretroviral therapy (ART) on protease inhibitor-based regimens. But lopinavir/ritonavir (LPV/r) syrup has many challenges in low-income countries, including limited availability, requires refrigeration, interactions with anti-tuberculous drugs, twice-daily dosing, poor palatability in young children, and higher cost...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzoxazines

Share to Burkina Faso

Share to Cote d'Ivoire

Share to Cyclopropanes

Share to Dideoxynucleosides

Share to Lopinavir

Share to Ritonavir

Source

Open in PubMed Open full text

Identifiers

PMID: 28434406
DOI: 10.1186/s12916-017-0842-4
PMCID: PMC5402051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.PMID 28434406Read ↗

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).Semantic proximity Read ↗

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trialSemantic proximity Read ↗

A trial of three antiretroviral regimens in HIV-1-infected children.Semantic proximity Read ↗

Lamivudine monotherapy in children and adolescents: The devil is in the detail.Semantic proximity Read ↗

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.Semantic proximity Read ↗

Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.Semantic proximity Read ↗

Paediatric antiretroviral therapy challenges with emerging integrase resistanceSemantic proximity Read ↗

Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.Semantic proximity Read ↗

Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial.Semantic proximity Read ↗

Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Semantic proximity Read ↗

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.Semantic proximity Read ↗

Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.